Saliva-based glucose device developer GBS sets terms for $20 million IPO

GBS, which is developing a saliva-based glucose monitoring system for diabetes in China, announced terms for its IPO on Thursday. The New York, NY-based company plans to raise $20 million by offering …
( read original story …)